News
Article
RetinalGenix Technologies begins testing remote ocular monitoring system
Author(s):
Key Takeaways
- RetinalGenix's prototype device uses near-infrared and green modes for enhanced imaging, enabling real-time remote monitoring without technicians or pupil dilation.
- The system facilitates immediate data access for remote physicians and connects patients with retinal specialists for screening and monitoring, not diagnostics.
The company announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes.
(Image Credit: AdobeStock/K Davis/peopleimages.com)
RetinalGenix Technologies Inc. announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes. As a result, the images will be further enhanced for inclusion in the second prototype and the design for manufacturing the prototype will begin.
The imaging system enables secure, real-time remote monitoring 24/7 from virtually any location. After the completion of the final prototype, the company will discuss installing units in numerous settings, including pharmacies, malls, general practices, specialty medical offices, hospitals, emergency rooms, urgent care facilities, nursing homes, and independent living facilities.
With easy operation and no required technician or pupil dilation to view a 40-degree field of vision needed, the system will also allow remote physicians to access data quickly for immediate assessment. It will even simultaneously capture retinal and external images of the patient’s eye.
After imaging, a specialized network of retinal specialists will be available to receive the images on a contracted basis. The specialists will be able to assist patients who may currently not have an eye care professional to review their results. However, the system is not for diagnostic purposes but is supposed to be used as a screening and monitoring tool. The system can lead to immediate resolution, either through a physical examination or by scheduling a visit to a doctor’s office.
"To prevent blindness, triage must occur in real-time, which typically does not happen under current circumstances," Jerry Katzman, CEO of RetinalGenix Technologies, said. "Additionally, the device must be available, affordable, accessible, and easy to use."
RetinalGenix has also been implementing the same strategy to find other opportunities to repurpose FDA-approved pharmaceuticals for the potential treatment to dry AMD, diabetic retinopathy, and dementia. The company has also submitted provisional patents for these treatments in the US and Europe.
Reference:
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring. RetinalGenix Technologies, Inc. Accessed February 24, 2025. RetinalGenix Technologies Breakthrough in Real-Time 24/7
